Description: BAX introduces its Dynamo Series smart stretcher, aiming to boost hospital safety and reduce patient transfers.

Description: DEERFIELD, Ill., January 13, 2026--BAXTER INTRODUCES THE DYNAMO SERIES, A NEW SMART STRETCHER TO HELP ADDRESS COMMON CHALLENGES IN HOSPITAL SETTINGS

Description: If you are wondering whether Baxter International's current share price reflects its underlying worth, this article is designed to help you break that question down clearly. The stock most recently closed at US$20.15, with returns of 1.3% over the past week, 5.2% over the past month, 3.3% year to date, but a 32.7% decline over one year, 51.5% decline over three years, and 72.0% decline over five years. These share price moves sit against a backdrop of ongoing attention on Baxter...

Description: Shares of healthcare company Baxter International (NYSE:BAX) fell 4.5% in the afternoon session after Barclays lowered its price target on the stock to $30 from $36, signaling a more cautious outlook on the company.

Description: CHARLESTON, S.C., January 08, 2026--MUSC Health and Baxter International Inc. (NYSE:BAX), a global medtech leader, are entering into a multi-year strategic partnership that aims to enhance the high-quality and safe patient care already delivered at MUSC Health, MUSC’s health care system, through integrated connected care technologies.

Description: DEERFIELD, Ill., January 06, 2026--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026. Andrew Hider, Baxter’s president and chief executive officer, is scheduled to present at 2:15 p.m. Pacific Time.

Description: Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund’s Investor Class fund ARTQX returned 0.97%, Advisor Class fund APDQX posted a return of 0.98%, and Institutional Class fund APHQX returned 0.97%, compared to […]

Description: Baxter International (BAX) has drawn fresh investor attention after recent trading, with the share price at $19.50 and mixed returns over the month and past 3 months prompting closer scrutiny of its fundamentals. See our latest analysis for Baxter International. The recent 1 day share price return of 2.04% and 1 month share price return of 5.18% sit against a 1 year total shareholder return decline of 33.07%. This indicates that short term momentum is improving, while longer term performance...

Description: In December 2025, Baxter International Inc. completed the final settlement of its cash tender offers, retiring all of its 2.600% senior unsecured notes due 2026 and purchasing a substantial portion of its 1.915% senior unsecured notes due 2027 for up to US$600,000,000 in aggregate, including US$2,610,000 of 2026 notes bought at US$960.50 per US$1,000 of principal plus accrued interest. By reducing near-term debt obligations through these tender offers, Baxter has adjusted its balance sheet...

Description: Baxter International Inc. (NYSE:BAX) is one of the top cheap stocks under $20 to buy now. On December 12, Wells Fargo analyst Larry Biegelsen reiterated a Hold rating on Baxter International Inc. (NYSE:BAX) on December 12 and set a price target of $19.00. The rating update came after Baxter International Inc. (NYSE:BAX) announced on December […]

Description: Non-PVC, environmentally friendly IV bags are gaining traction due to regulatory and health trends U.S. IV Bags Market U.S. IV Bags Market Dublin, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The "United States IV Bags Market Report by Material Type, Capacity, Chamber Type, States and Company Analysis, 2025-2033" has been added to ResearchAndMarkets.com's offering.The United States IV Bags Market is expected to grow substantially, increasing from US$ 595.98 million in 2024 to US$ 1.19 billion in 2033. This

Description: BAX is reshaping its portfolio following the divestiture of Kidney Care, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.

Description: We came across a bullish thesis on Baxter International Inc. on Value investing subreddit by Mr-Gambini. In this article, we will summarize the bulls’ thesis on BAX. Baxter International Inc.’s share was trading at $19.29 as of December 17th. BAX’s forward P/E was 8.12 according to Yahoo Finance. Baxter International (BAX) is a quintessential “boring but essential” medtech company operating in oligopolistic markets for […]

Description: Baxter shows EMR-integrated smart pumps cut safety alerts and speed IV setup, backed by real-world data from over a million infusions at ASHP 2025.

Description: Baxter International has lagged the broader health care sector by a wide margin over the past year, and analysts are taking a guarded stance on its outlook.

Description: Wondering if Baxter International is a beaten down healthcare name or a genuine value opportunity at today’s price? Let’s unpack what the market might be missing. The stock has inched up 2.3% over the last week and 3.6% over the past month, but that is against a much steeper backdrop with returns of -35.4% year to date and a -74.0% slide over five years. Investors have been reacting to Baxter’s ongoing portfolio reshaping, including moves to streamline its medical products business and...

Description: In early December 2025, Baxter International launched cash tender offers to buy back any and all of its 2.600% senior unsecured notes due 2026, and up to US$600 million of its 1.915% senior unsecured notes due 2027, as detailed in an amended offer to purchase document. At the same time, Baxter has been hit with multiple class action lawsuits and an FDA Class I recall over safety defects in its Novum IQ Large Volume Pump, raising fresh questions about product quality oversight and legal risk...

Description: DEERFIELD, Ill., December 11, 2025--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced data in collaboration with The University of Texas Medical Branch (UTMB Health) demonstrating the positive impact of smart infusion pump integration with hospital electronic medical records (EMRs) on patient safety, clinicians' bedside productivity and programming compliance. The analyses of more than one million infusions on Baxter’s Spectrum IQ

Description: Pzena Investment Management recently released its third-quarter 2025 commentary for “Pzena Focused Value Strategy.” A copy of the letter can be downloaded here. Driven by optimism about AI and a September rate cut, US broad-based indexes surged in the third quarter. The technology sector was the strongest performer, with growth outpacing value. The Pzena Focused […]

Description: Baxter International Inc. (NYSE:BAX) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On December 2, Morgan Stanley analyst Patrick Wood cut his price target on the stock to $15 from $19 while keeping an Underweight rating. Looking ahead to 2026, the analyst told investors in a research note that […]

Description: Market context and recent performance Baxter International (BAX) has been grinding through a tough stretch, with the stock down sharply over the past year. At the same time, revenue and net income have recently moved in opposite directions, with modest sales growth alongside a headline net loss. See our latest analysis for Baxter International. At around $18.54, Baxter’s 1 month share price return has turned slightly positive, but that sits against a much steeper year to date share price...

Description: Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Cullen Capital Management, LLC, operating under the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Enhanced Equity Income Fund” third-quarter investor letter. A copy of the letter can be downloaded here. US equities continued to rise in the third quarter, with the S&P 500 returning 8.1% while the Russell 1000 Value was up 5.3%. […]

Description: DEERFIELD, Ill., December 04, 2025--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes.

Description: DEERFIELD, Ill., December 04, 2025--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the early tender results for the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The tender offers are being made pursuant to the terms and conditions set forth in the offer to purchase, dated Nov. 19, 2025, as amended by the Company’s press release dated Nov. 19, 2025 (as it may be further amended or supplemented from time to tim

Description: Baxter recalls its Life2000 ventilation system over a serious cybersecurity flaw, pulling the device from the market despite no reported injuries.

Description: The respiratory care devices market is projected to grow from $24.16 billion in 2024 to $49.19 billion by 2033, at a CAGR of 8.22%. The rise is fueled by increasing cases of respiratory diseases such as asthma, COPD, and sleep apnea. Key devices include nebulizers, inhalers, CPAP machines, and ventilators, crucial for therapy and patient monitoring. Top players like Medtronic, Philips, GE Healthcare, and others are driving innovation. Sustainability efforts are notable among companies like Baxte

Description: Wondering if Baxter International is a hidden gem or a value trap? You're not alone, especially with the stock catching the eye of investors searching for a bargain. Despite a tough market stretch with a 20.1% dip over the past month and a dramatic 37.4% drop year-to-date, many are asking whether the risk has actually created new upside. In recent weeks, headlines have focused on Baxter's strategic moves, including updates around divestitures and streamlining its business operations. These...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: Oracle Corporation (NYSE: ORCL) today announced that it unanimously elected Stephen Rusckowski to Oracle's Board of Directors and increased the size of the Board to 14. The election is effective as of November 18, 2025.

Description: DEERFIELD, Ill., November 19, 2025--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the "2027 Notes Tender Offer") from $300 million to $600 million, on the terms and subject to the conditions set forth i

Description: DEERFIELD, Ill., November 19, 2025--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the commencement of tender offers, subject to the terms and conditions described below, to purchase for cash the debt securities issued by Baxter listed in the table below (collectively, the "Securities" and each a "series"). Subject to market conditions, the tender offers are expected to be funded using a portion of the proceeds from a concurrent offering of senior unsecured note

Description: The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio

Description: BSX's month-long rally, strong Q3 beats and expansion into chronic pain solutions sharpen investor focus.

Description: Baxter International Inc. (NYSE:BAX) is among the 13 Most Undervalued Stocks Under $20 to Buy. On October 31, Argus Research downgraded its rating of the stock to Hold from Buy. The adjustment followed the company’s third-quarter fiscal 2025 earnings call a day prior, in which it announced a significant reduction to its quarterly dividend to […]

Description: Baxter International (BAX) has drawn investor attention after posting third quarter results that showed higher sales but a net loss year over year. The company also provided updated guidance calling for moderate sales growth into 2025. See our latest analysis for Baxter International. The latest string of updates from Baxter International, including a modest dividend announcement and confirmation of moderate forward guidance, have not reversed its negative momentum. Even with a small lift in...

Description: DEERFIELD, Ill., November 11, 2025--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on Jan. 2, 2026, to stockholders of record as of Nov. 28, 2025. The indicated annual dividend rate equates to $0.04 per share of common stock.

Description: The Alpha-1 Antitrypsin Deficiency Disease market offers opportunities in developing targeted therapies due to an increasing diagnosed patient population, advances in genetic testing, and innovative treatments like enzyme replacement and gene therapies. Growing awareness and technological advancements further drive this niche market. Alpha-1 Antitrypsin Deficiency Disease Market Alpha-1 Antitrypsin Deficiency Disease Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Defic

Description: DEERFIELD, Ill., November 07, 2025--The Baxter Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the continuation of a partnership with Northwestern University’s School of Education and Social Policy (SESP) to provide science, technology, engineering and math (STEM) programs for students and teachers throughout the Chicagoland area. Supported by a three-year $2.6 million grant from the Foundation, the Baxter Center for Science Edu

Description: Baxter’s third quarter results were met with a negative market reaction, as the company delivered top-line growth but missed Wall Street’s revenue expectations. Management attributed performance shortfalls primarily to ongoing challenges in its Infusion Therapies & Technologies division, which faced a continued pause on Novum IQ Large Volume pump shipments, and to softness in U.S. demand for IV solutions. CEO Andrew Hider candidly stated, “We are not satisfied with our current performance,” emph

Description: Baxter International’s consensus analyst price target has seen a sharp decline recently, dropping from $28.00 per share to $24.07 per share. This reduction highlights a shift in sentiment, as it stems from mixed expectations about the company’s ability to overcome operational headwinds and sustain long-term growth. Stay tuned to discover how investors and observers can stay informed as the story around Baxter International’s outlook continues to evolve. Stay updated as the Fair Value for...

Description: Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and

Description: As Baxter International has underperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Description: Shares of healthcare company Baxter International (NYSE:BAX) fell 2.9% in the afternoon session after the stock continued to fall as the company reported mixed third-quarter results, lowered its full-year guidance, and announced a plan to reduce its dividend. While adjusted earnings per share of $0.69 beat expectations, revenue of $2.84 billion fell short of forecasts. The positive earnings were overshadowed by several concerns. The company's gross margin plunged due to product mix shifts and hi

Description: Healthcare company Baxter International (NYSE:BAX) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 5% year on year to $2.84 billion. Next quarter’s revenue guidance of $2.81 billion underwhelmed, coming in 6.5% below analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15.4% above analysts’ consensus estimates.

Description: The company's mixed quarterly results and uninspiring guidance led to a sell-off.

Description: Baxter International Inc (BAX) reports a 41% increase in adjusted EPS despite facing headwinds in its Infusion Therapies and Technologies division.

Description: Baxter International recently reported a third-quarter net loss of US$46 million despite year-on-year sales growth, with results shaped by ongoing legal and product safety challenges. Multiple class action lawsuits have been filed in response to defects and serious patient incidents involving the Novum IQ Large Volume Pump, raising concerns about safety controls and corporate disclosure practices. We will assess how these legal and product safety setbacks are now influencing Baxter...

Description: Shares of healthcare company Baxter International (NYSE:BAX) fell 13.5% in the morning session after the company reported disappointing third-quarter financial results, which included a miss on revenue and a weak outlook.

Description: While the top- and bottom-line numbers for Baxter (BAX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: Baxter's Q3 earnings top forecasts, but sales lag and 2025 EPS guidance slips; shares fall despite strength in Pharma and Advanced Surgery.

Description: Healthcare company Baxter International (NYSE:BAX) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 5% year on year to $2.84 billion. Next quarter’s revenue guidance of $2.81 billion underwhelmed, coming in 6.5% below analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15.4% above analysts’ consensus estimates.

Description: Baxter (BAX) delivered earnings and revenue surprises of +15.00% and -1.32%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: The Deerfield, Illinois-based company said it had a loss of 9 cents per share. Earnings, adjusted for one-time gains and costs, were 69 cents per share. The results topped Wall Street expectations.

Description: DEERFIELD, Ill., October 30, 2025--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025.

Description: Healthcare company Baxter International (NYSE:BAX) will be reporting earnings this Thursday before market hours. Here’s what investors should know.

Description: Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.

Description: Baxter International is slated to report its third-quarter earnings this week, with analysts expecting a low double-digit decline in profit amid ongoing industry and macroeconomic headwinds.

Description: Baxter International (BAX) shares have seen modest moves lately, catching the eye of investors interested in value after a challenging year for the stock. Recent returns suggest a mixed sentiment. This creates an interesting setup for those watching healthcare names. See our latest analysis for Baxter International. While Baxter International’s share price has bounced slightly in the last month, a steep drop in the past quarter leaves sentiment on shaky ground. With a 1-year total shareholder...

Description: Chris Barry, group president of medsurg at Solventum, is leaving the company at the end of the year in connection with Knight’s arrival.

Description: Solventum (NYSE: SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson.